Skystar Bio Pharmaceutical Company (SKBI)
-NasdaqCM 1.26 
0.08(5.90%) 3:25PM EDT - Nasdaq Real Time Price
| Prev Close: | 1.34 |
|---|
| Open: | 1.27 |
|---|
| Bid: | 1.26 x 300 |
|---|
| Ask: | 1.27 x 200 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.53 |
|---|
| Next Earnings Date: | 15-Aug-13 |
|---|
| Day's Range: | 1.26 - 1.28 |
|---|
| 52wk Range: | 1.00 - 2.31 |
|---|
| Volume: | 5,121 |
|---|
| Avg Vol (3m): | 17,113 |
|---|
| Market Cap: | 9.59M |
|---|
| P/E (ttm): | 1.92 |
|---|
| EPS (ttm): | 0.66 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SKYSTAR BIO-PHARMACEUTICAL CO FinancialsEDGAR Online Financials(Tue, May 21)
- Skystar Bio - Pharmaceutical Company's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 16)
- Skystar Bio-Pharmaceutical Reports First Quarter 2013 ResultsMarketwired(Thu, May 16)
- SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- Skystar to File Financial Results for First Quarter of 2013 on Wednesday, May 15, 2013Marketwired(Tue, May 14)
- Form 10 K for Skystar Bio-Pharmaceutical CompanyWILink(Wed, Apr 24)
- Skystar Bio-Pharmaceutical Reports Fiscal Year 2012 Financial ResultsMarketwired(Tue, Apr 2)
- SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
- Skystar to File Audited Financial Results for Full Fiscal Year 2012 on Monday April 1, 2013Marketwired(Mon, Apr 1)
- Skystar Bio-Pharmaceutical Engages Protiviti, a Leading Provider of Consulting and Internal Audit ServicesMarketwired(Tue, Mar 26)
- Skystar Bio-Pharmaceutical Announces Results for Third Quarter Fiscal Year 2012Marketwired(Thu, Nov 15)
- SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Nov 14)
- Skystar to File Unaudited Third Quarter Fiscal Year 2012 Financial Results on Wednesday, November 14, 2012Marketwired(Wed, Nov 14)
- Skystar's New Vaccine Facility in Huxian Passes Initial GMP CertificationMarketwired(Tue, Nov 13)
- Skystar's Primary Veterinary Medication Facility in Huxian Province Resumes Production and DistributionMarketwired(Mon, Nov 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 0.33 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 5.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Skystar Bio-Pharmaceutical Company, through its subsidiaries, engages in the research, development, production, marketing, and sale of veterinary healthcare and medical care products in the Peoples Republic of China.
View More